-
AstraZeneca Turned to AI to Speed Discovery of New Medicines for IPF
The prognosis remains poor for patients living with idiopathic pulmonary fibrosis (IPF) and collaborations to enhance and expedite treatment options are crucial to patient survival. A recent collaboration has been announced by AstraZeneca to speed the discovery of new medicines for IPF, which is discussed in our latest flash briefing. To listen to the full briefing, click HERE.
What are your thoughts on this flash briefing?
An interesting, but complex and seemingly promising advancement for those of us living with IPF!
Sorry, there were no replies found.
Log in to reply.